BUFFALO, NY -- (Marketwire) -- 02/06/12 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 14th Annual BIO CEO and Investor Conference, February 13-14, in New York, NY.
Neil Lyons, Chief Financial Officer for Cleveland BioLabs, will give a presentation on February 14 at 3:00 p.m. Eastern Time. A live and archived webcast of the Company's presentation will be available on the investor page of the Cleveland BioLabs web site at www.cbiolabs.com.
Cleveland BioLabs is developing a pipeline of products for multiple defense and medical applications from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation and chemotherapy. Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer agents.
For more information about the 14th Annual BIO CEO and Investor Conference, please visit http://www.bio.org/events/conferences/14th-annual-bio-ceo-investor-conference.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of nine compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a direct acting anticancer agent. The Company has two subsidiaries, Incuron, LLC and Pancela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors.
These factors include, among others, the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; the Company's need for substantial additional financing to meet its business objectives; the potential for the loss of funding from the Company's R&D grants and contracts; the Company's failure to successfully and timely develop new products; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's collaborative relationships and the financial risks related thereto; the Company's ability to comply with its obligations under license agreements; the potential for significant product liability claims; and the Company's ability to comply with various safety, environmental and other governmental regulations. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439